Literature DB >> 1372352

Susceptibility of HIV-1 isolates to zidovudine: correlation between widely applicable culture test and PCR analysis.

M Jung1, H Agut, D Candotti, D Ingrand, C Katlama, J M Huraux.   

Abstract

Thirteen isolates of human immunodeficiency virus type 1 (HIV-1) obtained in coculture with peripheral blood lymphocytes were tested for in vitro susceptibility to zidovudine (ZDV). Seven isolates were obtained from patients who had never been treated with ZDV and six from patients receiving the drug. The seven isolates from untreated patients and four of six from treated patients were susceptible to ZDV. The two isolates from the patients treated for the longest periods were resistant to the drug. The presence of mutations at critical positions of the reverse transcriptase gene was investigated by direct sequencing of polymerase chain reaction (PCR)-amplified DNA and four isolates were found to be mutants. An isolate from an untreated patient showed a change at residue 70 of the reverse transcriptase and an isolate from a patient treated for 4 months showed a change at residue 67. A change at residue 215 was found only for the two drug-resistant isolates, which correlated with the results obtained by Larder et al. using isolates from MT-2 cell cocultures. These results suggest that any HIV isolate provided by conventional coculture could be confidently tested for ZDV susceptibility in order to study the emergence of resistance during long-term therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1372352

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  11 in total

1.  Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors.

Authors:  B Masquelier; E Race; C Tamalet; D Descamps; J Izopet; C Buffet-Janvresse; A Ruffault; A S Mohammed; J Cottalorda; A Schmuck; V Calvez; E Dam; H Fleury; F Brun-Vézinet
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 2.  Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  P Muir; U Kämmerer; K Korn; M N Mulders; T Pöyry; B Weissbrich; R Kandolf; G M Cleator; A M van Loon
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

3.  Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection.

Authors:  G Carcelain; R Tubiana; A Samri; V Calvez; C Delaugerre; H Agut; C Katlama; B Autran
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

4.  Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.

Authors:  Anne-Geneviève Marcelin; Isabelle Cohen-Codar; Martin S King; Philippe Colson; Emmanuel Guillevic; Diane Descamps; Claire Lamotte; Véronique Schneider; Jacques Ritter; Michel Segondy; Hélène Peigue-Lafeuille; Laurence Morand-Joubert; Anne Schmuck; Annick Ruffault; Pierre Palmer; Marie-Laure Chaix; Vincent Mackiewicz; Véronique Brodard; Jacques Izopet; Jacqueline Cottalorda; Evelyne Kohli; Jean-Pierre Chauvin; Dale J Kempf; Gilles Peytavin; Vincent Calvez
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

5.  Emergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detection.

Authors:  M B Vasudevachari; Y M Zhang; H Imamichi; T Imamichi; J Falloon; N P Salzman
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

6.  Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients.

Authors:  Martin S King; Richard Rode; Isabelle Cohen-Codar; Vincent Calvez; Anne-Geneviève Marcelin; George J Hanna; Dale J Kempf
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

7.  Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group.

Authors:  D L Mayers; A J Japour; J M Arduino; S M Hammer; R Reichman; K F Wagner; R Chung; J Lane; C S Crumpacker; G X McLeod
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

8.  Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.

Authors:  Anne-Geneviève Marcelin; Claire Lamotte; Constance Delaugerre; Nadine Ktorza; Hocine Ait Mohand; Raquel Cacace; Manuela Bonmarchand; Marc Wirden; Anne Simon; Philippe Bossi; François Bricaire; Dominique Costagliola; Christine Katlama; Gilles Peytavin; Vincent Calvez
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

9.  Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group.

Authors:  A J Japour; D L Mayers; V A Johnson; D R Kuritzkes; L A Beckett; J M Arduino; J Lane; R J Black; P S Reichelderfer; R T D'Aquila
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

10.  Deciphering the complex distribution of human immunodeficiency virus type 1 subtypes among different cohorts in Northern Tanzania.

Authors:  Harr F Njai; Fiona M Ewings; Eric Lyimo; Vincent Foulongne; Dhamira Ngerageza; Aika Mongi; Deogratius Ssemwanga; Aura Andreasen; Balthazar Nyombi; Tony Ao; Denna Michael; Mark Urassa; Jim Todd; Basia Zaba; John Changalucha; Richard Hayes; Saidi H Kapiga
Journal:  PLoS One       Date:  2013-12-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.